The European regulatory landscape for medical technologies is currently undergoing its most significant transformation in decades as agencies strive to balance rapid scientific advancement with the non-negotiable requirement for patient safety. This shift moves away from a one-size-fits-all
The integration of next-generation sequencing into routine clinical practice represents a major leap forward for oncology, moving beyond invasive tissue extraction toward highly sensitive liquid biopsy techniques that monitor circulating tumor DNA in the bloodstream. The oncNGS project, reaching
The halls of the Stockholm Exhibition Center hummed with a palpable sense of urgency during the 2026 MedTech Forum, where healthcare leaders gathered to address a growing divide in global medical technology accessibility. Industry experts and European regulators find themselves at a crossroads
The European medical device landscape has shifted from a period of frantic regulatory activity to a phase of pronounced stagnation as the momentum behind new certification standards continues to dissipate. After years of rapid expansion driven by the transition to more stringent frameworks, the
The silent progression of metabolic disorders often occurs beneath the surface of apparent health, leaving many individuals unaware of their condition until significant physiological damage has already taken root. For decades, the medical community operated on a reactive basis, identifying diabetes
The current landscape of European healthcare stands at a critical juncture where the promise of life-saving medical technology frequently clashes with the rigid constraints of a maturing regulatory framework. While the European Union’s Medical Devices Regulation and In Vitro Diagnostics Regulation
